FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023622543> ?p ?o ?g. }

• W2023622543 endingPage "77" @default.
• W2023622543 startingPage "64" @default.
• W2023622543 abstract "Background: Lumiracoxib is a cyclooxygenase-2-selectiveinhibitor developed for the treatment of osteoarthritis (OA), rheumatoid arthritis, and acute pain. Objectives: This study assessed the efficacy and tolerability of lumiracoxib 100 mg QD compared with celecoxib and placebo in patients with OA of the knee. Methods: In this 13-week, double-blind, double-dummy,placebo-controlled, parallel-group study, patients with primary OA of the knee and pain intensity in the target knee a40 mm on a 100-mm visual analog scale after a 3- to 7-day washout of nonsteroidal anti-inflammatory drugs were randomized to receive lumiracoxib 100 mg QD, lumiracoxib 100 mg QD with a loading dose of lumiracoxib 200 mg QD for the first 2 weeks, celecoxib 200 mg QD, or placebo. Three primary efficacy variables were assessed at the end of the study: pain intensity in the target knee, the patient's global assessment of disease activity, and functional status (Western Ontario and McMaster Universities Osteoarthritis Index total score). In addition, the treatment response was assessed using the Outcome Measures in Clinical Trials-Osteoarthritis Research Society International (OMERACT OARSI) criteria. The safety profile and tolerability of all treatments were also examined. Results: The study enrolled 1551 patients (primarily white; 62% female; mean age, 60.5 years): 391 were randomized to receive lumiracoxib 100 mg QD, 385 lumiracoxib 100 mg QD with a loading dose, 393 celecoxib 200 mg QD, and 382 placebo. Treatment groups were closely balanced at baseline with respect to demographic and disease characteristics. Lumiracoxib was superior to placebo (P < 0.001) and similar to celecoxib on all primary efficacy variables. Reductions in pain intensity in the target knee were similar in the 2 lumiracoxib groups at week 13 (estimated least square mean difference vs placebo: −6.7 and −8.1 mm for lumiracoxib 100 mg QD and lumiracoxib 100 mg QD with loading dose, respectively; both, P < 0.001); with celecoxib, the estimated least square mean difference was −5.7 mm (P < 0.001). Significant differences compared with placebo were seen in all variables starting at week 2 for all active treatments (all, P < 0.001). No significant differences were seen between the lumiracoxib groups at any time point. Based on OMERACT OARSI criteria, all active treatments were superior to placebo (all, P < 0.001). Lumiracoxib and celecoxib were well tolerated, with an incidence of adverse events similar to that with placebo (64.7% lumiracoxib 100 mg QD, 67.0% lumiracoxib 100 mg QD with loading dose, 58.8% celecoxib, 58.4% placebo). Conclusion: In this population of patients with OA of the knee, lumiracoxib 100 mg QD was of similar efficacy to celecoxib 200 mg QD and had similar tolerability to placebo." @default.
• W2023622543 created "2016-06-24" @default.
• W2023622543 creator A5000786936 @default.
• W2023622543 creator A5006354171 @default.
• W2023622543 creator A5045796345 @default.
• W2023622543 creator A5070492560 @default.
• W2023622543 creator A5071730263 @default.
• W2023622543 creator A5082336063 @default.
• W2023622543 date "2005-01-01" @default.
• W2023622543 modified "2023-09-30" @default.
• W2023622543 title "Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo" @default.
• W2023622543 cites W1524988749 @default.
• W2023622543 cites W1980913979 @default.
• W2023622543 cites W1981816788 @default.
• W2023622543 cites W2012801178 @default.
• W2023622543 cites W2019253219 @default.
• W2023622543 cites W2020846765 @default.
• W2023622543 cites W2057685090 @default.
• W2023622543 cites W2058147305 @default.
• W2023622543 cites W2074493159 @default.
• W2023622543 cites W2076744535 @default.
• W2023622543 cites W2084256772 @default.
• W2023622543 cites W2104379105 @default.
• W2023622543 cites W2115805053 @default.
• W2023622543 cites W2118840514 @default.
• W2023622543 cites W2124433729 @default.
• W2023622543 cites W2142606962 @default.
• W2023622543 cites W2161097107 @default.
• W2023622543 cites W2163306078 @default.
• W2023622543 cites W2164323898 @default.
• W2023622543 cites W2330496155 @default.
• W2023622543 cites W2610860323 @default.
• W2023622543 cites W4239471829 @default.
• W2023622543 cites W4255015940 @default.
• W2023622543 doi "https://doi.org/10.1016/j.clinthera.2005.01.002" @default.
• W2023622543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15763607" @default.
• W2023622543 hasPublicationYear "2005" @default.
• W2023622543 type Work @default.
• W2023622543 sameAs 2023622543 @default.
• W2023622543 citedByCount "60" @default.
• W2023622543 countsByYear W20236225432012 @default.
• W2023622543 countsByYear W20236225432013 @default.
• W2023622543 countsByYear W20236225432014 @default.
• W2023622543 countsByYear W20236225432015 @default.
• W2023622543 countsByYear W20236225432016 @default.
• W2023622543 countsByYear W20236225432017 @default.
• W2023622543 countsByYear W20236225432018 @default.
• W2023622543 countsByYear W20236225432019 @default.
• W2023622543 countsByYear W20236225432020 @default.
• W2023622543 countsByYear W20236225432021 @default.
• W2023622543 crossrefType "journal-article" @default.
• W2023622543 hasAuthorship W2023622543A5000786936 @default.
• W2023622543 hasAuthorship W2023622543A5006354171 @default.
• W2023622543 hasAuthorship W2023622543A5045796345 @default.
• W2023622543 hasAuthorship W2023622543A5070492560 @default.
• W2023622543 hasAuthorship W2023622543A5071730263 @default.
• W2023622543 hasAuthorship W2023622543A5082336063 @default.
• W2023622543 hasConcept C126322002 @default.
• W2023622543 hasConcept C14184104 @default.
• W2023622543 hasConcept C142724271 @default.
• W2023622543 hasConcept C168563851 @default.
• W2023622543 hasConcept C197934379 @default.
• W2023622543 hasConcept C204787440 @default.
• W2023622543 hasConcept C27081682 @default.
• W2023622543 hasConcept C2776164576 @default.
• W2023622543 hasConcept C2776467144 @default.
• W2023622543 hasConcept C2777575956 @default.
• W2023622543 hasConcept C2778375690 @default.
• W2023622543 hasConcept C42219234 @default.
• W2023622543 hasConcept C71924100 @default.
• W2023622543 hasConceptScore W2023622543C126322002 @default.
• W2023622543 hasConceptScore W2023622543C14184104 @default.
• W2023622543 hasConceptScore W2023622543C142724271 @default.
• W2023622543 hasConceptScore W2023622543C168563851 @default.
• W2023622543 hasConceptScore W2023622543C197934379 @default.
• W2023622543 hasConceptScore W2023622543C204787440 @default.
• W2023622543 hasConceptScore W2023622543C27081682 @default.
• W2023622543 hasConceptScore W2023622543C2776164576 @default.
• W2023622543 hasConceptScore W2023622543C2776467144 @default.
• W2023622543 hasConceptScore W2023622543C2777575956 @default.
• W2023622543 hasConceptScore W2023622543C2778375690 @default.
• W2023622543 hasConceptScore W2023622543C42219234 @default.
• W2023622543 hasConceptScore W2023622543C71924100 @default.
• W2023622543 hasIssue "1" @default.
• W2023622543 hasLocation W20236225431 @default.
• W2023622543 hasLocation W20236225432 @default.
• W2023622543 hasOpenAccess W2023622543 @default.
• W2023622543 hasPrimaryLocation W20236225431 @default.
• W2023622543 hasRelatedWork W1990986050 @default.
• W2023622543 hasRelatedWork W1991350847 @default.
• W2023622543 hasRelatedWork W2024586323 @default.
• W2023622543 hasRelatedWork W2030566772 @default.
• W2023622543 hasRelatedWork W2050532333 @default.
• W2023622543 hasRelatedWork W2063216433 @default.
• W2023622543 hasRelatedWork W2120551915 @default.
• W2023622543 hasRelatedWork W2161097107 @default.
• W2023622543 hasRelatedWork W2604269157 @default.
• W2023622543 hasRelatedWork W3169016788 @default.

• next